Acylcarnitines profile best predicts survival in horses with atypical myopathy

[en] Equine atypical myopathy (AM) is caused by hypoglycin A intoxication and is characterized by a high fatality rate. Predictive estimation of survival in AM horses is necessary to prevent unnecessary suffering of animals that are unlikely to survive and to focus supportive therapy on horses with a possible favourable prognosis of survival. We hypothesized that outcome may be predicted early in the course of disease based on the assumption that the acylcarnitine profile reflects the derangement of muscle energetics. We developed a statistical model to prognosticate the risk of death of diseased animals and found that estimation of outcome may be drawn from three acylcarnitines (C2, C10:2 and C18 -carnitines) with a high sensitivity and specificity. The calculation of the prognosis of survival makes it possible to distinguish the horses that will survive from those that will die despite severe sign of acute rhabdomyolysis in both groups

Research center :

FARAH - Fundamental and Applied Research for Animals and Health - ULiège

Disciplines :

Veterinary medicine & animal health

Author, co-author :

BOEMER, François ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique

Detilleux, Johann ; Université de Liège - ULiège > Département des productions animales (DPA) > Génétique quantitative

CELLO, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Service de génétique

Amory, Hélène ; Université de Liège - ULiège > Dép. clinique des animaux de compagnie et des équidés (DCA) > Médecine interne des équidés

Marcillaud-Pitel, Christel

Richard, Eric

Van Galen, Gaby

van Loon, Gunther

Lefère, Laurence

Votion, Dominique ; Université de Liège - ULiège > Scientifiques attachés au Doyen (F MV)

Language :

English

Title :

Acylcarnitines profile best predicts survival in horses with atypical myopathy

Alternative titles :

[fr] Le profil des acylcarnitines prédit la survie chez les chevaux souffrant de myopathie atypique

Publication date :

30 January 2017

Journal title :

PLoS ONE

eISSN :

1932-6203

Publisher :

Public Library of Science, San Franscisco, United States - California

Pages :

1-16

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1371/journal.

Funders :

IFCE - Institut Français du Cheval et de l'Équitation [FR]
ULiège FSR - Université de Liège. Fonds spéciaux pour la recherche [BE]

Available on ORBi :

since 18 September 2017

Statistics

Number of views

143 (39 by ULiège)

Number of downloads

28 (14 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Baise E, Habyarimana JA, Amory H, Boemer F, Douny C, Gustin P, et al. Samaras and seedlings of Acer pseudoplatanus are potential sources of hypoglycin A intoxication in atypical myopathy without necessarily inducing clinical signs. Equine veterinary Journal. 2015. https://doi.org/10.1111/evj.12499 PMID: 26278545
Votion DM, van Galen G, Sweetman L, Boemer F, de Tullio P, Dopagne C, et al. Identification of methy-lenecyclopropyl acetic acid in serum of European horses with atypical myopathy. Equine Vet J. 2014; 46(2):146–9. https://doi.org/10.1111/evj.12117 PMID: 23773055.
Westermann CM, van Leeuwen R, van Raamsdonk LW, Mol HG. Hypoglycin A Concentrations in Maple Tree Species in the Netherlands and the Occurrence of Atypical Myopathy in Horses. J Vet Intern Med. 2016; 30(3):880–4. https://doi.org/10.1111/jvim.13927 PMID: 26995161.
Westermann CM, Dorland L, Votion DM, de Sain-van der Velden MG, Wijnberg ID, Wanders RJ, et al. Acquired multiple Acyl-CoA dehydrogenase deficiency in 10 horses with atypical myopathy. Neuromus-cul Disord. 2008; 18(5):355–64. Epub 2008/04/15. S0960-8966(08)00037-0 [pii] https://doi.org/10.1016/j.nmd.2008.02.007 PMID: 18406615.
Bochnia M, Ziegler J, Sander J, Uhlig A, Schaefer S, Vollstedt S, et al. Hypoglycin A content in blood and urine discriminates horses with atypical myopathy from clinically normal horses grazing on the same pasture. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0136785 PMID: 26378918
Sander J, Cavalleri JM, Terhardt M, Bochnia M, Zeyner A, Zuraw A, et al. Rapid diagnosis of hypoglycin A intoxication in atypical myopathy of horses. J Vet Diagn Invest. 2016; 28(2):98–104. https://doi.org/10.1177/1040638715624736 PMID: 26965229.
Boemer F, Deberg M, Schoos R, Baise E, Amory H, Gault G, et al. Quantification of hypoglycin A in plasma using aTRAQ(R) kit. Journal of Chromatography B. 2015; 997:75–80.
van Galen G, Marcillaud Pitel C, Saegerman C, Patarin F, Amory H, Baily JD, et al. European outbreaks of atypical myopathy in grazing equids (2006–2009): Spatiotemporal distribution, history and clinical features. Equine Vet J. 2012; 44(5):614–20. Epub 2012/03/28. https://doi.org/10.1111/j.2042-3306.2012.00556.x PMID: 22448904.
van Galen G, Votion DM. Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 1: First aid, cardiovascular, nutritional and digestive care. Equine Veterinary Education. 2013; 25(5):264–70.
van Galen G, Votion DM. Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 2: Muscular, urinary, respiratory and hepatic care, and inflammatory/infectious status. Equine Veterinary Education. 2013; 25(6):264–70.
van Galen G, Saegerman C, Marcillaud Pitel C, Patarin F, Amory H, Baily JD, et al. European outbreaks of atypical myopathy in grazing horses (2006–2009): Determination of indicators for risk and prognostic factors. Equine Vet J. 2012; 44(5):621–5. Epub 2012/03/15. https://doi.org/10.1111/j.2042-3306.2012.00555.x PMID: 22413891.
Gonzalez-Medina S, Ireland JL, Piercy RJ, Newton JR, Votion DM. Equine Atypical Myopathy in the UK: Epidemiological characteristics of cases reported from 2011 to 2015 and factors associated with survival. Equine Vet J. 2017. https://doi.org/10.1111/evj.12694 PMID: 28445006.
Carlier J, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L, et al. A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 978–979:70–7. https://doi.org/10.1016/j.jchromb.2014.11.029 PMID: 25531872
Boemer F, Deberg M, Schoos R, Baise E, Amory H, Gault G, et al. Quantification of hypoglycin A in serum using aTRAQ(R) assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 997:75–80. https://doi.org/10.1016/j.jchromb.2015.06.004 PMID: 26094208.
Chace DH, Pons R, Chiriboga CA, McMahon DJ, Tein I, Naylor EW, et al. Neonatal blood carnitine concentrations: normative data by electrospray tandem mass spectometry. Pediatr Res. 2003; 53(5):823–9. Epub 2003/03/04. https://doi.org/10.1203/01.PDR.0000059220.39578.3D 01. PDR.0000059220.39578.3D [pii]. PMID: 12612202.
Filee R, Schoos R, Boemer F. Evaluation of physiological amino acids profiling by tandem mass spectrometry. J Inherit Metab Dis. 2014; 13:119–28.
Detilleux J, Arendt J, Lomba F, Leroy P. Methods for estimating areas under receiver-operating characteristic curves: illustration with somatic-cell scores in subclinical intramammary infections. Prev Vet Med. 1999; 41(2–3):75–88. PMID: 10448938.
Esbjørn Høffer S, Votion DM, Andeberg M, Boemer F, Nautrup Olsen S, Van Galen G. Atypical Myopathy in Denmark Confirmed With the aTRAQ Assay. Journal of Equine Veterinary Science. 2016;(47):77–9.
McKenzie RK, Hill FI, Habyarimana JA, Boemer F, Votion DM. Detection of hypoglycin A in the seeds of sycamore (Acer pseudoplatanus) and box elder (A. negundo) in New Zealand; the toxin associated with cases of equine atypical myopathy. N Z Vet J. 2016; 64(3):182–7. https://doi.org/10.1080/00480169.2015.1123123 PMID: 26593855.
Votion DM, Linden A, Delguste C, Amory H, Thiry E, Engels P, et al. Atypical myopathy in grazing horses: a first exploratory data analysis. The Veterinary Journal. 2009; 180(1):77–87. Epub 2008/04/09. S1090-0233(08)00037-3 [pii] https://doi.org/10.1016/j.tvjl.2008.01.016 PMID: 18396430.
Votion DM, Linden A, Saegerman C, Engels P, Erpicum M, Thiry E, et al. History and clinical features of atypical myopathy in horses in Belgium (2000–2005). Journal of Veterinary Internal Medicine. 2007; 21 (6):1380–91. Epub 2008/01/17. PMID: 18196750.
van Galen G, Cerri S, Porter S, Saegerman C, Lefere L, Roscher K, et al. Traditional and quantitative assessment of Acid-base and shock variables in horses with atypical myopathy. J Vet Intern Med. 2013; 27(1):186–93. Epub 2012/12/01. https://doi.org/10.1111/jvim.12003 PMID: 23193982.
Verheyen T, Decloedt A, De Clercq D, van Loon G. Cardiac changes in horses with atypical myopathy. J Vet Intern Med. 2012; 26(4):1019–26. Epub 2012/06/01. https://doi.org/10.1111/j.1939-1676.2012.00945.x PMID: 22646196.
Von Holt C. Methylenecyclopropaneacetic acid, a metabolite of hypoglycin. Biochim Biophys Acta. 1966; 125(1):1–10. Epub 1966/08/03. 0005-2760(66)90138-X [pii]. PMID: 5968592.
Tanaka K, Kean EA, Johnson B. Jamaican vomiting sickness. Biochemical investigation of two cases. N Engl J Med. 1976; 295(9):461–7. Epub 1976/08/26. https://doi.org/10.1056/NEJM197608262950901 PMID: 940578.
Barceloux DG. Akee fruit and Jamaican vomiting sickness (Blighia sapida Koenig). Dis Mon. 2009; 55 (6):318–26. Epub 2009/05/19. S0011-5029(09)00027-3 [pii] https://doi.org/10.1016/j.disamonth.2009.03.002 PMID: 19446675.
Shih VE, Tanaka K. Plasma and urine amino acid changes in rats treated with hypoglycin. Clin Chim Acta. 1978; 88(3):539–43. Epub 1978/09/15. PMID: 699343.
Delguste C, Cassart D, Baise E, Linden A, Schwarzwald C, Feige K, et al. Myopathies atypiques chez les chevaux au pré: une série de cas en Belgique. Ann Med Vet. 2002; 146:231–43.
Grunes DE, Scordi-Bello I, Suh M, Florman S, Yao J, Fiel MI, et al. Fulminant hepatic failure attributed to Ackee fruit ingestion in a patient with sickle cell trait. Case Reports in Transplantation. 2012;(Article ID 739238):4 pages. https://doi.org/10.1155/2012/739238 PMID: 23259140
Osmundsen H, Sherratt HS. A novel mechanism for inhibition of beta-oxidation by methylenecyclopro-pylacetyl-CoA, a metabolite of hypoglycin. FEBS Lett. 1975; 55(1):38–41. Epub 1975/07/15. PMID: 1140426.
Tanaka K, Miller EM, Isselbacher KJ. Hypoglycin A: a specific inhibitor of isovaleryl CoA dehydrogenase. Proc Natl Acad Sci U S A. 1971; 68(1):20–4. Epub 1971/01/01. PMID: 5276292; PubMed Central PMCID: PMC391092.
Tanaka K. On the mode of action of hypoglycin A. 3. Isolation and identification of cis-4-decene-1,10-dioic, cis, cis-4,7-decadiene-1,10-dioic, cis-4-octene-1,8-dioic, glutaric, and adipic acids, N-(methylene-cyclopropyl)acetylglycine, and N-isovalerylglycine from urine of hypoglycin A-treated rats. J Biol Chem. 1972; 247(23):7465–78. PMID: 4636318.
Ikeda Y, Tanaka K. Selective inactivation of various acyl-CoA dehydrogenases by (methylenecyclopro-pyl)acetyl-CoA. Biochim Biophys Acta. 1990; 1038(2):216–21. Epub 1990/04/19. 0167-4838(90)90208-W [pii]. PMID: 2331485.
Lai MT, Li D, Oh E, Liu HW. Inactivation of medium-chain acyl-CoA dehydrogenase by a metabolite of hypoglycin: characterization of the major turnover product and evidence suggesting an alternative flavin modification pathway. J Am Chem Soc. 1993; 115(5):1619–28.
Entman M, Bressler R. The mechanism of action of hypoglycin on long-chain fatty acid oxidation. Mol Pharmacol. 1967; 3(4):333–40. Epub 1967/07/01. PMID: 6033633.